NLRP3 and dry eye syndrome: Collectively, it can be inferred that Eva1a ameliorates hepatic I/R injury by inhibiting NLRP3 activation through promoting autophagy via the ATG5/ATG12 pathway in KCs, which suggests that Eva1a can be used as a clinical drug target to intervene hepatic I/R injury in the future [85].